Page 1 | Search Results | Blood Advances | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study

Blood Adv bloodadvances.2024014903.

https://doi.org/10.1182/bloodadvances.2024014903

Published: 2024

Includes: Supplemental data

Journal Articles

CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

Fabiana Perna, Samir Parekh, Caroline Diorio, Melody Smith, Marion Subklewe, Rakesh Mehta, Frederick L. Locke, Nirali N. Shah

Blood Adv (2024) 8 (16): 4348–4358.

https://doi.org/10.1182/bloodadvances.2024013044

Published: 2024

Journal Articles

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Kai Rejeski, Yucai Wang, Doris K. Hansen, Gloria Iacoboni, Emmanuel Bachy, Radhika Bansal, Olaf Penack, Fabian Müller, Wolfgang Bethge, Javier Munoz, Razan Mohty, Veit L. Bücklein, Pere Barba, Frederick L. Locke, Yi Lin, Michael D. Jain, Marion Subklewe

Blood Adv (2024) 8 (8): 1857–1868.

https://doi.org/10.1182/bloodadvances.2023011767

Published: 2024

Includes: Supplemental data

Journal Articles

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Blood Adv (2023) 7 (22): 6844–6849.

https://doi.org/10.1182/bloodadvances.2023010364

Published: 2023

Includes: Supplemental data

Journal Articles

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

Maria-Luisa Schubert, Wolfgang A. Bethge, Francis A. Ayuk, Malte von Bonin, Vladan Vucinic, Eva Marie Wagner-Drouet, Marion Subklewe, Claudia D. Baldus, Bertram Glass, Reinhard Marks, Dimitrios Mougiakakos, Roland Schroers, Matthias Stelljes, Max S. Topp, Gerald Wulf, Nicolaus Kröger, Peter Dreger

Blood Adv (2023) 7 (20): 6191–6195.

https://doi.org/10.1182/bloodadvances.2023011203

Published: 2023

Includes: Supplemental data

Journal Articles

The race is on: bispecifics vs CAR T cells in B-cell lymphoma

Ashwath Gurumurthi, Jason Westin, Marion Subklewe

Blood Adv (2023) 7 (19): 5713–5716.

https://doi.org/10.1182/bloodadvances.2022009066

Published: 2023

Journal Articles

Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy

Blood Adv (2023) 7 (10): 2066–2069.

https://doi.org/10.1182/bloodadvances.2022007806

Published: 2023

Includes: Supplemental data

Journal Articles

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Kai Rejeski, Andreas Burchert, Gloria Iacoboni, Pierre Sesques, Lars Fransecky, Veit Bücklein, Corinna Trenker, Rafael Hernani, Ralph Naumann, Jonas Schäfer, Viktoria Blumenberg, Christian Schmidt, Kristina Sohlbach, Michael von Bergwelt-Baildon, Emmanuel Bachy, Pere Barba, Marion Subklewe

Blood Adv (2022) 6 (16): 4719–4725.

https://doi.org/10.1182/bloodadvances.2022007776

Published: 2022

Includes: Supplemental data

Journal Articles

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Blood Adv (2022) 6 (12): 3606–3610.

https://doi.org/10.1182/bloodadvances.2021006922

Published: 2022

Includes: Supplemental data

Journal Articles

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment

Florian Schoeberl, Steffen Tiedt, Anita Schmitt, Viktoria Blumenberg, Philipp Karschnia, Vanessa Granja Burbano, Veit L. Bücklein, Kai Rejeski, Christian Schmidt, Galina Busch, Michael von Bergwelt-Baildon, Jörg-Christian Tonn, Michael Schmitt, Marion Subklewe, Louisa von Baumgarten

Blood Adv (2022) 6 (10): 3022–3026.

https://doi.org/10.1182/bloodadvances.2021006144

Published: 2022

Journal Articles

BiTEs better than CAR T cells

Marion Subklewe

Blood Adv (2021) 5 (2): 607–612.

https://doi.org/10.1182/bloodadvances.2020001792

Published: 2021

Journal Articles

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis

Victoria V. Grunwald, Marcus Hentrich, Xaver Schiel, Annika Dufour, Stephanie Schneider, Michaela Neusser, Marion Subklewe, Michael Fiegl, Wolfgang Hiddemann, Karsten Spiekermann, Maja Rothenberg-Thurley, Klaus H. Metzeler

Blood Adv (2019) 3 (18): 2696–2699.

https://doi.org/10.1182/bloodadvances.2019000265

Published: 2019

Includes: Supplemental data

NARROW

Safety and Efficacy of Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma in a Multinational Real-World Study

CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations

Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality

Early quantification of anti-CD19 CAR T cells by flow cytometry predicts response in R/R DLBCL

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study

The race is on: bispecifics vs CAR T cells in B-cell lymphoma

Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy

Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

Neurofilament light chain serum levels correlate with the severity of neurotoxicity after CAR T-cell treatment

BiTEs better than CAR T cells

Patients with spontaneous remission of high-risk MDS and AML show persistent preleukemic clonal hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only